Interstitial lung diseases (ILDs) represent a heterogeneous group of more than 200 lung disorders, primarily affecting the pulmonary interstitium. These disorders are characterized by fibrosis, inflammation, or a combination of both. ILDs are often complex, requiring a comprehensive understanding of their causes, symptoms, and treatment options.
ILDs can be idiopathic or associated with a myriad of causes, such as connective tissue diseases, occupational and environmental exposures, drugs, and radiation. Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic ILD, with a poorly understood etiology. It is believed that genetic predisposition, aging, and environmental factors like smoking contribute to the development of IPF.
ILDs typically present with insidious onset of dyspnea and non-productive cough. Physical examination may reveal inspiratory crackles and finger clubbing. High-resolution computed tomography (HRCT) is the gold standard for diagnosis, showing characteristic patterns such as reticular opacities, honeycombing, and ground-glass opacities. Pulmonary function tests often reveal a restrictive pattern with reduced diffusion capacity.
Management of ILDs depends on the underlying cause. In cases of IPF, antifibrotic agents like pirfenidone and nintedanib have shown to slow disease progression. For ILDs associated with connective tissue diseases, immunosuppressive therapy is often beneficial. Lung transplantation remains the ultimate treatment for selected patients with advanced disease.
ILDs are a diverse group of lung disorders with varying etiologies and clinical presentations. A thorough understanding of the causes, symptoms, and treatment options is essential for optimal patient management. Future research should focus on elucidating the pathogenesis of idiopathic ILDs and developing novel therapeutic strategies.
1.
Talquetamab Combos Show Survival Benefit in r/r Myeloma
2.
From sweetener to cancer fighter? Fermented stevia shows promise in pancreatic cancer study
3.
Year in Review: Non-Small Cell Lung Cancer
4.
FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.
5.
Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML
1.
Targeted Therapies for Breast Cancer: What’s New?
2.
Ultrasound: A Promising Tool in the Fight Against Malignant Breast Cancer
3.
Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role
4.
Revolutionizing Cancer Care: The Transformative Role of AI and Data Science in Oncology
5.
Sorafenib: Understanding the science behind a powerful cancer drug
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
2.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
4.
Common Cancer Myths Debunked
5.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation